Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...
FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient ...
Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...
While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...
Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...
Sonrotoclax (BGB-11417), an investigational, next-generation BCL2 inhibitor, has received priority review designation from the FDA for the treatment of adult patients with relapsed or refractory (R/R) ...
Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...
The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in treating nonsquamous NSCLC. The study confirmed comparable efficacy and ...
The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...
A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...
RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...
The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback